诺诚健华医药有限公司（股票代码：09969）于2026年9月17日发布翌日披露报表，披露已发行股本变动情况。
公告显示，诺诚健华医药有限公司在上海证券交易所科创板上市的人民币普通股（A股）方面，因根据2024年人民币股股份激励计划预留授予部分的第一期归属结果，向86名参与人发行新人民币股份合计581,137股，占之前该类别已发行股份（不含库藏股）约0.03%，每股发行价格为人民币6.65元，发行总金额合计约386.46万元人民币。发行完成后，科创板已发行人民币普通股数量增至273,403,904股。
同时，公告显示，公司在香港联交所上市的普通股数量及库藏股数量并未发生变化，仍分别维持在1,493,798,235股和2,486,000股。
公司董事会正式授权此次股份授予并确认，已遵守相关上市规则和适用法律法规。公告由公司主席兼执行董事崔霽松博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.